Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NS
| City: |
|
Knoxville |
| State: |
|
Tennessee |
| Zip Code: |
|
37916 |
| Conditions: |
|
Lung Cancer - Non Small Cell |
| Purpose: |
|
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin
will extend the lives of patients with squamous only non small cell lung cancer more than
placebo plus Paclitaxel and Carboplatin.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Non small cell lung cancer (NSCLC) - squamous cell
- Stage IV or recurrent NSCLC
- Eastern Cooperative Oncology Group (ECOG) of 0 or 1
Exclusion Criteria:
- Brain Metastases
- Autoimmune diseases
|
| NCT ID: |
|
NCT01285609 |
| Primary Contact: |
|
Study Director
Bristol-Myers Squibb
Bristol-Myers Squibb
For participation information at a USA site use a phone number below. For site information outside the USA please email:
Email: Clinical.Trials@bms.com
|
| Backup Contact: |
|
First line of email MUST contain NCT# & Site#. Only trial sites that are recruiting have contact information at this time.
|
| Location Contact: |
|
Knoxville, Tennessee 37916
United States
Site 010
Site Status: Not yet recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 23, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|